Approved by the Drugs Controller General of India (DCGI), it goes beyond glycemic control, overcoming broader obstacles associated with diabetes care

Akums Drugs and Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets; an advanced combination therapy designed to tackle the growing challenge of diabetes management. The dual-action formulation offers a more potent solution for individuals struggling with existing metformin-based regimens. Approved by the Drugs Controller General of India (DCGI), it goes beyond glycemic control, overcoming broader obstacles associated with diabetes care.

The dual-action therapy combines two complementary mechanisms of action. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, aids in eliminating excess glucose via urine while delivering additional benefits such as improved cardiovascular and renal outcomes, along with better weight management. Pioglitazone, on the other hand, augments insulin sensitivity in key tissues, such as muscles and the liver, helping combat the root issue of insulin resistance. Together, they provide sustained results while minimising risks like hypoglycemia and weight gain, which are common hurdles in diabetes care. 

Compared to monotherapy, this dual approach ensures more comprehensive blood sugar regulation by addressing multiple pathways simultaneously. While single-drug regimens may provide partial benefits, the combined action of Dapagliflozin and Pioglitazone offers superior control, reducing fluctuations in glucose levels more effectively. Moreover, dual therapy lowers the likelihood of treatment failure, ensuring long-term stability without necessitating frequent medication adjustments. It is a once-daily dosing that further enhances adherence, making diabetes management simpler and seamless for patients.

Sandeep Jain, Managing Director, Akums Drugs and Pharmaceuticals, stated, “The rise in diabetes cases in our country calls for novel and accessible solutions. By introducing Dapagliflozin + Pioglitazone tablets, we aim to equip healthcare providers with an advanced treatment option that caters to the diverse needs faced by patients. Our goal is to deliver therapies that make a real difference in people’s lives.”

Sanjeev Jain, MD, Akums, noted, “The fight against diabetes requires a collaborative effort between healthcare providers, patients, and pharmaceutical innovators. Managing the condition often presents significant lifestyle hurdles for those affected. At Akums, we are committed to elevating well-being and enabling sound health outcomes. Backed by robust research, this dual-action therapy is developed to progress patient outcomes and overall well-being.”